这一年半,很多互联网医疗公司已经融不到钱了,或者大家开始质疑他们的商业模式。我觉得再过一两年,很多互联网医疗公司将陷入财务困境并很难生存下去近两年来,很多原本不是投医药的基金都开始希望在这个领域有所布局。但我觉得现在的局面有点乱新药研发领域是我所看好的。我们三年前所投的再鼎医药,在不到三年的时间里就拿到不少于八个药的授权,它的增长比我们想象的要快得多。但问题在于,贝达药业上市,以及前两年美国的很多新药研发公司上市,引起投资者一窝蜂地涌入新药 This year and a half, many Internet health care companies have been unable to melt the money, or we began to question their business model. I think in the next year or two, many internet medical companies will be in financial difficulties and will have difficulty surviving. In the past two years, many funds that were not originally intended to be used in medicine started to hope that they will be laid out in this area. But I think the situation is a bit chaotic New Drug R & D area is what I am optimistic about. ZD Medicine, which we invested three years ago, got the authorization of not less than eight drugs in less than three years and its growth is much faster than we think. The problem, however, is that Beida Pharmaceutical went public and that many new drug discovery companies listed in the United States two years ago brought investors swarming into new drugs